CNS Pharmaceuticals (CNSP) Income towards Parent Company (2018 - 2025)

CNS Pharmaceuticals (CNSP) has 8 years of Income towards Parent Company data on file, last reported at -$6.0 million in Q4 2025.

• Quarterly Income towards Parent Company fell 87.13% year-over-year to -$6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$16.0 million (down 7.28% YoY) and the FY2025 annual result came in at -$34.8 million, down 15.25% from the prior year.
• Income towards Parent Company eased to -$6.0 million in Q4 2025, from -$3.3 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$2.4 million in Q2 2025 to a low of -$6.0 million in Q4 2025.
• A 5-year average of -$4.0 million and a median of -$3.7 million in 2021 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2021 — Income towards Parent Company slumped 89.67% — and 2025, when it surged 42.19%.
• Tracing CNSP's Income towards Parent Company over 5 years: stood at -$3.3 million in 2021, then plunged by 57.89% to -$5.1 million in 2022, then declined by 4.76% to -$5.4 million in 2023, then surged by 40.54% to -$3.2 million in 2024, then sank by 87.13% to -$6.0 million in 2025.
• The last three Income towards Parent Company figures came in at -$6.0 million (Q4 2025), -$3.3 million (Q3 2025), and -$2.4 million (Q2 2025), per Business Quant data.